CALCB
Calcitonin gene-related peptide 2
As of the edition of 20 October 2026, CALCB (calcitonin gene-related peptide 2, UniProt P10092) has 3 drugs tested at it and 6 companies on the list, 0 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10092
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Disease areas
- Nervous system; Mental health; Bones, joints and muscles; Ear, nose and throat; Mouth and teeth; Pregnancy and women's health; Urinary and reproductive; Cancer
- Registered trials of its drugs
- 97
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fremanezumab | Marketed | Phase 4 | Ends 2030 |
| Galcanezumab | Marketed | Phase 4 | Ends 2030 |
| Eptinezumab | Marketed | Phase 4 | Ends 2032 |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 4 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 6 |
The other 3 companies at CALCB
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at CALCB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.